2026-04-29T13:12:14Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/183982024-05-28T11:50:02Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16968col_20.500.12105_16978col_20.500.12105_16983col_20.500.12105_16988
Repisalud author Buxeda, Anna author Arias-Cabrales, Carlos author Pérez-Sáez, María José author Cacho, Judit author Cabello Pelegrin, Sheila author Melilli, Edoardo author Aladrén, María José author Galeano, Cristina author Lorenzo, Inmaculada author Mazuecos, Auxiliadora author Saura, Isabel María author Franco, Antonio author Ruiz-Fuentes, María Del Carmen author Sánchez-Cámara, Luis Alberto author Siverio, Orlando author Martin, María Luisa author González-García, Elena author López, Verónica author Martin-Moreno, Paloma Leticia author Moina, Iñigo author Moral Berrio, Esperanza author Moreso, Francesc author Portolés, José María author Santana-Estupiñán, Raquel author Zárraga, Sofía author Canal, Cristina author Sánchez-Álvarez, Emilio author Pascual, Julio author Crespo, Marta 2024-02-19T15:29:31Z 2024-02-19T15:29:31Z 2021-07-06 10.1016/j.ekir.2021.06.023 2468-0249 Kidney international reports http://hdl.handle.net/10668/18190 34250317 http://hdl.handle.net/20.500.12105/18398 Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidney transplant recipients. We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treated with remdesivir. Outcomes and safety were assessed. Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5 years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) required mechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged ≥65 years (45% vs. 3.2% in younger patients). Acute kidney injury was present in 27.7% of patients, but was diagnosed in 50% before treatment. No patients required remdesivir discontinuation because of adverse events. We did not find significant hepatoxicity or systemic symptoms resulting from the drug. In our cohort of kidney transplant recipients, remdesivir was well tolerated and safe in renal and hepatic toxicity, but randomized trials are needed to assess its efficacy. eng SARS-CoV-2 Acute kidney injury Immunosuppression Kidney transplantation Remdesivir Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19 research article